Market Overview
Gilead
GILD is a leading biopharma with a durable HIV franchise and a scaling oncology portfolio. Biktarvy (U.S. exclusivity to 2036) underpins predictable cash flows to fund growth in oncology and inflammation.
Key Catalysts
HIV Leadership: Biktarvy’s longevity funds pipeline; lenacapavir (long-acting prevention) adds medium-term upside.
Oncology Momentum: Trodelvy growth across breast/bladder; pipeline enhanced by assets like Repare’s Polθ inhibitor.
Visibility: Multiple Phase 3 readouts through 2026 support multi-year revenue/EPS clarity.
Investment Outlook
Bullish above: $105–$108
Target: $150–$155 — supported by HIV cash durability, oncology expansion, and late-stage catalysts.
#GILD #Biopharma #Oncology #HIV #Lenacapavir #Trodelvy
Gilead
GILD is a leading biopharma with a durable HIV franchise and a scaling oncology portfolio. Biktarvy (U.S. exclusivity to 2036) underpins predictable cash flows to fund growth in oncology and inflammation.Key Catalysts
HIV Leadership: Biktarvy’s longevity funds pipeline; lenacapavir (long-acting prevention) adds medium-term upside.
Oncology Momentum: Trodelvy growth across breast/bladder; pipeline enhanced by assets like Repare’s Polθ inhibitor.
Visibility: Multiple Phase 3 readouts through 2026 support multi-year revenue/EPS clarity.
Investment Outlook
Bullish above: $105–$108
Target: $150–$155 — supported by HIV cash durability, oncology expansion, and late-stage catalysts.
#GILD #Biopharma #Oncology #HIV #Lenacapavir #Trodelvy
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.